Every material Form 8-K Dare Bioscience, Inc. has filed with the SEC since September 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Daré Bioscience received a Nasdaq letter dated September 28, 2026, stating that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The letter has no immediate effect on the stock's listing, but the company has until March 29, 2027 to regain compliance, and failure to do so could lead to delisting proceedings unless it qualifies for an additional compliance period.
Nasdaq letter received September 28, 2026 cites the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2)
Compliance Date is March 29, 2027, a 180-calendar-day initial period
Regaining compliance requires a closing bid price of at least $1.00 for 10 consecutive business days, unless Nasdaq extends that period
A reverse stock split may be needed if the company seeks an additional 180-day period; the company states there is no assurance it will regain compliance
Daré Bioscience filed a Form 8-K furnishing a corporate presentation dated October 1, 2026, to be used in meetings with securities market participants beginning that day. The filing is a routine disclosure under Regulation FD and contains no reported financial results, guidance, or transactions.
Corporate presentation dated October 1, 2026 furnished as Exhibit 99.1
Company will use the presentation in meetings with securities market participants starting October 1, 2026
A copy will be posted in the Investors section of the company's website; the information is furnished, not filed
Daré Bioscience filed a Form 8-K furnishing a corporate presentation dated September 9, 2026, as Exhibit 99.1, for use in meetings with securities market participants starting that day. The filing is administrative and contains no financial results, guidance, or deal terms in the text provided, and the presentation content was not included in the filing text.
Corporate presentation dated September 9, 2026 furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure)
Company plans to use the presentation in investor meetings commencing September 9, 2026
Presentation to be posted on the Investors section of the company website, ir.darebioscience.com
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Dare Bioscience, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →